Daiichi Sankyo Korea, Daewoong to co-promote hypertensive agent in combination form

Daiichi Sankyo Korea has joined hands with Daewoong Pharm to market Sevicar, a combination of the angiotensin II receptor antagonist olmesartan, and the calcium channel blocker amlodipine) from July 10.

Sevicar is a convenient, once daily, single tablet combination of amlodipine, the most prescribed calcium channel blocker on the market, which inhibits the entrance of calcium into the blood ...